CYP450 and Its Implications in the Clinical Use of Antipsychotic Drugs
Identificadores
URI: http://hdl.handle.net/20.500.12020/777ISSN: 2161-1459
DOI: 10.4172/2161-1459.1000176
Autor/es
Mora, Fernando; Molina Martín, Juan de Dios; Zubillaga, Elena; López-Muñoz, F.; Álamo González, CFecha
2015-05-25Tipo de documento
articleÁrea/s de conocimiento
PsicologíaResumen
Polypharmacy implies a high potential for drug-drug interactions. The capacity of the cytochrome P450 enzyme
system involved in the metabolism of psychoactive drugs differs greatly, which leads to variable drug elimination rates
and inter-subject differences in serum drug concentrations. Polymorphisms in genes coding for CYP450 enzymes
contribute to this inter-subject variability. Therapeutic response and adverse effects vary among patients treated with
the same dose of a certain drug. Polypharmacy, comorbidity and the use of certain substances (grapefruit juice,
caffeine and tobacco) increase the chances of clinically relevant interactions in a psychotic patient. Choosing drugs
with low interaction potential seems to be the best strategy to prevent clinically relevant interactions particularly in
elderly, polymedicated, oncologic and HIV patients.